Prospective Analysis of TEL/AML1-positive Patients Treated on Dana-Farber Cancer Institute Consortium Protocol 95-01

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2006 Feb 24

PMID 16493009

Citations 33

Authors

Mignon L Loh

Meredith A Goldwasser

Lewis B Silverman

Wing-Man Poon

Shashaank Vattikuti

Angelo Cardoso

Donna S Neuberg

Kevin M Shannon

Stephen E Sallan

D Gary Gilliland

Affiliations

Soon will be listed here.

Abstract

In a retrospective analysis, we previously reported that children whose leukemia cells harbored the TEL/AML1 gene rearrangement have excellent outcomes. From 1996 to 2000, we conducted a prospective study to determine the incidence and outcomes of children with TEL/AML1-positive acute lymphoblastic leukemia (ALL). Children with newly diagnosed ALL were treated on DFCI ALL Consortium Protocol 95-01. Patients were risk stratified primarily by current National Cancer Institute (NCI)-Rome risk criteria. With a median follow-up of 5.2 years, the 5-year event-free survival for TEL/AML1-positive patients was 89% compared with 80% for TEL/AML1-negative B-precursor patients (P = .05). The 5-year overall survival rate was 97% among TEL/AML-positive patients compared with 89% among TEL/AML1-negative patients (P = .03). However, in a multivariable analysis, risk group (age and leukocyte count at diagnosis) and asparaginase treatment group, but not TEL/AML1 status, were found to be independent predictors of outcome. We conclude that TEL/AML1-positive patients have excellent outcomes, confirming our previous findings. However, factors such as age at diagnosis and presenting leukocyte count should be taken into consideration when treating this group of patients.

Citing Articles

Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies.

Purvis K, Zhou Y, Karol S, Rubnitz J, Ribeiro R, Lee S Blood. 2024; 145(2):190-201.

PMID: 39316653 PMC: 11738036. DOI: 10.1182/blood.2024024936.

Acute lymphoblastic leukaemia.

Pagliaro L, Chen S, Herranz D, Mecucci C, Harrison C, Mullighan C Nat Rev Dis Primers. 2024; 10(1):41.

PMID: 38871740 DOI: 10.1038/s41572-024-00525-x.

Gene expression prognostic of early relapse risk in low-risk B-cell acute lymphoblastic leukaemia in children.

Gong X, Hu T, Shen Q, Zhang L, Zhang W, Liu X EJHaem. 2024; 5(2):333-345.

PMID: 38633121 PMC: 11020147. DOI: 10.1002/jha2.872.

Generation of a Zebrafish Knock-In Model Recapitulating Childhood ETV6::RUNX1-Positive B-Cell Precursor Acute Lymphoblastic Leukemia.

Zapilko V, Moisio S, Parikka M, Heinaniemi M, Lohi O Cancers (Basel). 2023; 15(24).

PMID: 38136366 PMC: 10871125. DOI: 10.3390/cancers15245821.

Stem cell mutations, associated cancer risk, and consequences for regenerative medicine.

Derks L, van Boxtel R Cell Stem Cell. 2023; 30(11):1421-1433.

PMID: 37832550 PMC: 10624213. DOI: 10.1016/j.stem.2023.09.008.

References

Whitehead V, Vuchich M, Cooley L, Lauer S, Mahoney D, Shuster J . Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Leuk Lymphoma. 1999; 31(5-6):507-19. DOI: 10.3109/10428199809057610. View

Loh M, Silverman L, Young M, Neuberg D, Golub T, Sallan S . Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood. 1998; 92(12):4792-7. View

Wiemels J, Cazzaniga G, Daniotti M, Eden O, Addison G, Masera G . Prenatal origin of acute lymphoblastic leukaemia in children. Lancet. 1999; 354(9189):1499-503. DOI: 10.1016/s0140-6736(99)09403-9. View

Arico M, Valsecchi M, Camitta B, Schrappe M, Chessells J, Baruchel A . Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000; 342(14):998-1006. DOI: 10.1056/NEJM200004063421402. View

Ramakers-Van Woerden N, Pieters R, Loonen A, Hubeek I, van Drunen E, Beverloo H . TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood. 2000; 96(3):1094-9. View

Silverman L, Gelber R, Dalton V, Asselin B, Barr R, Clavell L . Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001; 97(5):1211-8. DOI: 10.1182/blood.v97.5.1211. View

Hann I, Vora A, Harrison G, Harrison C, Eden O, Hill F . Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol. 2001; 113(1):103-14. DOI: 10.1046/j.1365-2141.2001.02668.x. View

Krishna Narla R, Navara C, Sarquis M, Uckun F . Chemosensitivity of TEL-AML1 fusion transcript positive acute lymphoblastic leukemia cells. Leuk Lymphoma. 2001; 41(5-6):615-23. DOI: 10.3109/10428190109060352. View

Seeger K, von Stackelberg A, Taube T, Buchwald D, Korner G, Suttorp M . Relapse of TEL-AML1--positive acute lymphoblastic leukemia in childhood: a matched-pair analysis. J Clin Oncol. 2001; 19(13):3188-93. DOI: 10.1200/JCO.2001.19.13.3188. View

10.

Ford A, Fasching K, Panzer-Grumayer E, Koenig M, Haas O, Greaves M . Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes. Blood. 2001; 98(3):558-64. DOI: 10.1182/blood.v98.3.558. View

11.

Pui C, Campana D, Evans W . Childhood acute lymphoblastic leukaemia--current status and future perspectives. Lancet Oncol. 2002; 2(10):597-607. DOI: 10.1016/S1470-2045(01)00516-2. View

12.

Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P . Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood. 2002; 99(8):2734-9. DOI: 10.1182/blood.v99.8.2734. View

13.

Loh M, Rubnitz J . TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches. Curr Opin Hematol. 2002; 9(4):345-52. DOI: 10.1097/00062752-200207000-00013. View

14.

Stams W, den Boer M, Beverloo H, Meijerink J, Stigter R, van Wering E . Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood. 2002; 101(7):2743-7. DOI: 10.1182/blood-2002-08-2446. View

15.

Pui C, Relling M, Downing J . Acute lymphoblastic leukemia. N Engl J Med. 2004; 350(15):1535-48. DOI: 10.1056/NEJMra023001. View

16.

Zuna J, Ford A, Peham M, Patel N, Saha V, Eckert C . TEL deletion analysis supports a novel view of relapse in childhood acute lymphoblastic leukemia. Clin Cancer Res. 2004; 10(16):5355-60. DOI: 10.1158/1078-0432.CCR-04-0584. View

17.

Sallan S, Gelber R, Cassady J, Frei 3rd E, Nathan D . Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983; 43(11):5601-7. View

18.

Golub T, Barker G, Lovett M, Gilliland D . Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994; 77(2):307-16. DOI: 10.1016/0092-8674(94)90322-0. View

19.

Golub T, Barker G, Bohlander S, Hiebert S, Ward D, Morgan E . Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 1995; 92(11):4917-21. PMC: 41818. DOI: 10.1073/pnas.92.11.4917. View

20.

Romana S, Mauchauffe M, Le Coniat M, Chumakov I, Le Paslier D, Berger R . The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood. 1995; 85(12):3662-70. View